GI
CRMD icon

Gradient Investments’s CorMedix CRMD Stock Holding History

Gradient Investments’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-50
Closed – – 1240
2022
Q1 		$0 Hold
50
– – ﹤0.01% 1201
2021
Q4 		$0 Hold
50
– – ﹤0.01% 1243
2021
Q3 		$0 Hold
50
– – ﹤0.01% 1154
2021
Q2 		$0 Hold
50
– – ﹤0.01% 1165
2021
Q1 		$0 Buy
+50
New +$526 ﹤0.01% 1174

Other funds holding CRMD

Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Gradient Investments's CRMD Position: Q2 2022 in Review

Gradient Investments sold out of CorMedix (CRMD) in Q2 2022, closing a stake of 50 shares.

Gradient Investments first reported a position in CRMD in Q1 2021 and held it in 5 quarters. The position peaked at $0 in Q1 2022. 74 funds tracked by Wall St. Rank hold CRMD as of Q2 2022.

  • Gradient Investments reported no remaining CorMedix position as of Q2 2022 after selling out during the quarter.
  • Gradient Investments sold 50 CorMedix shares in Q2 2022.
  • Gradient Investments first reported a position in CorMedix in Q1 2021 and held it in 5 quarters.
  • Gradient Investments's CorMedix position peaked at $0 in Q1 2022.
  • 74 funds tracked by Wall St. Rank held CorMedix as of Q2 2022.

Based on Gradient Investments's 13F filing for Q2 2022, filed 11 Jul 2022.